Cue Biopharma Inc (CUE)
1.02
-0.01
(-0.97%)
USD |
NASDAQ |
Nov 22, 16:00
1.05
+0.03
(+2.94%)
After-Hours: 20:00
Cue Biopharma Cash from Investing (Quarterly): 0.098M for Sept. 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 0.098M |
| June 30, 2024 | -0.01M |
| March 31, 2024 | -0.055M |
| December 31, 2023 | 0.00 |
| September 30, 2023 | 5.00M |
| June 30, 2023 | 5.00M |
| March 31, 2023 | 15.00M |
| December 31, 2022 | 4.999M |
| September 30, 2022 | -29.52M |
| June 30, 2022 | -0.062M |
| March 31, 2022 | -0.027M |
| December 31, 2021 | 0.0005M |
| September 30, 2021 | -0.011M |
| June 30, 2021 | -0.233M |
| March 31, 2021 | 9.352M |
| December 31, 2020 | 9.892M |
| Date | Value |
|---|---|
| September 30, 2020 | 4.654M |
| June 30, 2020 | -0.14M |
| March 31, 2020 | -9.95M |
| December 31, 2019 | -15.15M |
| September 30, 2019 | 3.984M |
| June 30, 2019 | 5.127M |
| March 31, 2019 | 9.481M |
| December 31, 2018 | 4.687M |
| September 30, 2018 | -23.61M |
| June 30, 2018 | -0.76M |
| March 31, 2018 | -0.673M |
| December 31, 2017 | -0.019M |
| September 30, 2017 | -0.208M |
| June 30, 2017 | -0.422M |
| March 31, 2017 | -0.556M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-29.52M
Minimum
Sep 2022
15.00M
Maximum
Mar 2023
-0.0578M
Average
-0.005M
Median
Cash from Investing (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | -16.16M |
| Arbutus Biopharma Corp | -11.99M |
| GlycoMimetics Inc | 0.00 |
| FibroGen Inc | 0.755M |
| Cidara Therapeutics Inc | -0.106M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -7.527M |
| Cash from Financing (Quarterly) | 9.821M |
| Free Cash Flow | -38.32M |
| Free Cash Flow Per Share (Quarterly) | -0.1469 |
| Free Cash Flow to Equity (Quarterly) | -6.568M |
| Free Cash Flow Yield | -75.88% |